
What Stands in the Way of Abundance in Healthcare?
Recent public initiatives to manufacture insulin highlight both the promise and pitfalls of the new politics of “abundance.” Although states are capable of producing high-quality, affordable medicines, these efforts inevitably face resistance from powerful private interests. Without recognizing this as a central obstacle and building the political will to overcome it, plans to expand public production, in healthcare or elsewhere, are unlikely to succeed.